ProQR Therapeutics (NASDAQ:PRQR) Cut to Hold at StockNews.com

StockNews.com lowered shares of ProQR Therapeutics (NASDAQ:PRQR) from a buy rating to a hold rating in a research report released on Friday morning.

PRQR has been the topic of several other research reports. Chardan Capital reaffirmed a neutral rating and issued a $2.00 target price on shares of ProQR Therapeutics in a report on Friday, August 4th. HC Wainwright reissued a buy rating and set a $5.00 price objective on shares of ProQR Therapeutics in a report on Monday, August 7th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, ProQR Therapeutics presently has an average rating of Moderate Buy and a consensus price target of $3.88.

ProQR Therapeutics Stock Down 4.3 %

Shares of NASDAQ:PRQR opened at $1.54 on Friday. The firm’s 50 day moving average price is $1.59 and its 200 day moving average price is $1.98. The stock has a market cap of $124.46 million, a price-to-earnings ratio of -2.11 and a beta of -0.02. ProQR Therapeutics has a fifty-two week low of $0.72 and a fifty-two week high of $3.85. The company has a quick ratio of 5.71, a current ratio of 5.71 and a debt-to-equity ratio of 0.07.

ProQR Therapeutics (NASDAQ:PRQR) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.01. The firm had revenue of $1.31 million for the quarter, compared to analysts’ expectations of $2.77 million. ProQR Therapeutics had a negative net margin of 1,427.27% and a negative return on equity of 86.23%. As a group, equities research analysts predict that ProQR Therapeutics will post -0.25 earnings per share for the current fiscal year.

Hedge Funds Weigh In On ProQR Therapeutics

Hedge funds have recently modified their holdings of the business. Belvedere Trading LLC purchased a new position in shares of ProQR Therapeutics during the fourth quarter worth approximately $42,000. Tower Research Capital LLC TRC grew its position in shares of ProQR Therapeutics by 164.8% during the first quarter. Tower Research Capital LLC TRC now owns 14,132 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 8,796 shares during the last quarter. Mariner LLC purchased a new position in shares of ProQR Therapeutics during the fourth quarter worth approximately $68,000. Two Sigma Securities LLC purchased a new position in shares of ProQR Therapeutics during the first quarter worth approximately $41,000. Finally, Vanguard Personalized Indexing Management LLC purchased a new position in shares of ProQR Therapeutics during the fourth quarter worth approximately $79,000. 26.15% of the stock is currently owned by hedge funds and other institutional investors.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).